Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients

Annals of Oncology

Volumn 13, Issue 2, 2002, Pages 308-317

  Kohne C H ^a   Cunningham, D ^b   Di Costanzo, F ^c   Glimelius, B ^d   Blijham, G ^e   Aranda, E ^f   Scheithauer, W ^g   Rougier, P ^a   Palmer, M ^h   Wils, J ⁱ   Baron, B ^j   Pignatti, F ^j   Schoffski P ^k   Micheel, S ^l   Hecker, H ^k  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c S MARIA HOSPITAL   (Italy)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g UNIVERSITY OF VIENNA   (Austria)

^h ASTRAZENECA   (United Kingdom)

ⁱ LAURENTIUS HOSPITAL   (Netherlands)

^j EORTC DATA CENTER   (Belgium)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l Section of Pathology   (Germany)

more..

Author keywords

Colorectal neoplasm; Metastatic disease; Multivariate analysis; Prognosis

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; HEMOGLOBIN; HYDROXYUREA; INTERFERON; METHOTREXATE; MITOMYCIN C; MOLECULAR MARKER; RALTITREXED; SPARFOSIC ACID;

ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; HIGH RISK POPULATION; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; METHODOLOGY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZATION; RECTUM CANCER; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL TIME; THROMBOCYTE; TREATMENT OUTCOME; VALIDATION PROCESS;

ALKALINE PHOSPHATASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUKOCYTE COUNT; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROSPECTIVE STUDIES;

EID: 0036302615     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf034     Document Type: Article

References (49)

1. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
2. Survival benefit of chemotherapy in metastatic colorectal cancer: A meta-analysis of randomized controlled trials
3. First-line chemotherapy for colorectal carcinoma-we are making progress
4. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience
5. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count
6. Appraisal of a model for prediction of prognosis in advanced colorectal cancer
7. Determinants of prognosis in advanced colorectal cancer
8. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer
9. Meta-analysis of alpha-interferon plus 5-fluorouracil in advanced colorectal cancer
10. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer
11. Phase II evaluation of 5-fluorouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer
12. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: A prospective randomized trial
13. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure 1-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study
14. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Therapy (TTD) study
15. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer
16. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer
17. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer
18. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer
19. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: Final results of a randomized European Organization for Research and Treatment of Cancer Study
20. Double modulation of high dose 5-fluorouracil (FU) with low dose PALA and methotrexate (MTX): Results of a randomized EORTC study
21. Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
22. High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research
23. Hydroxyurea (HU), high dose folinic acid (l-FA) and 5-FU vs. HU, 5FU and interferon-alpha-2b (IFN) in advanced colorectal cancer (ACRC): A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
24. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer
25. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial
26. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial
27. 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
28. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
29. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU+LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial
30. Tree-structured prediction for censored survival data and the Cox model
31. Regression models and life-tables
32. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid
33. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer
34. Survival and response to chemotherapy for advanced colorectal adenocarcinoma
35. Prognostic factors of advanced colorectal cancer patients
36. Weekly high dose infusional (CI) 5-FU plus folinic acid (FA) has major impact on survival in patients with advanced colorectal cancer. Results of a multivariate analysis using RECPAM
37. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy
38. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: An Eastern Cooperative Oncology Group report
39. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
40. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
41. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
42. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
43. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer
44. First line irinotecan (C), Fluorouracil (F), Leukovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favorable prognostic indicators
45. Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy
46. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
47. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
48. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil
49. Analysis of the p53/BAX pathway in colorectal cancer: Low BAX is a negative prognostic factor in patients with resected liver metastases